Meet Our Featured Speakers

The peptide therapeutics market is expanding rapidly, driven by rising demands for targeted, high-efficacy treatments across metabolic disorders, oncology, cardiovascular diseases, and rare conditions. Industry analysts project the global peptide therapeutics market to surpass €75 billion by the mid-2030s, supported by strong clinical pipelines and growing regulatory approvals. While injectable peptides remain the leading modality, the industry is undergoing a pivotal shift towards advanced delivery strategies that enhance bioavailability, stability, and patient adherence. Oral peptide delivery, including oral GLP-1 formulations, represents a major frontier, alongside methods such as permeation enhancers, enzyme inhibition, and protease-resistant peptide development. At the same time, new therapeutic applications continue to arise, broadening peptide use across chronic and long-term treatment settings.

Pharmaceutical and biotechnology companies are investing extensively in peptide innovation, supported by advancements in synthesis, formulation, and delivery platforms. Long-acting peptides are gaining momentum through half-life extension approaches such as lipidation, PEGylation, and albumin-binding technologies, allowing weekly, monthly, or even quarterly dosing schedules. These advancements significantly lessen treatment burden and enhance patient adherence. Controlled-release depots, injectable sustained-release formulations, and implantable systems enable predictable pharmacokinetics over prolonged periods. At the same time, oral and non-invasive delivery technologies continue to progress through clinical advancement, positioning peptides as practical alternatives to traditional small molecules and biologics for an expanding range of indications. However, the global peptide delivery landscape remains deeply interconnected, requiring collaboration across regions, supply chains, and advancement partners.

Overcoming Biological Barriers in Peptide Delivery

Peptide drugs face inherent delivery challenges, including enzymatic degradation, low membrane permeability, and limited oral bioavailability. As a result, delivery science is now central to commercial success. Novel formulation approaches such as nanoparticle carriers, self-nanoemulsifying drug delivery systems (SNEDDS), and cell-penetrating peptides are advancing to protect peptides and support efficient transport across biological barriers. Injectable depot technologies and long-acting formulations address the requirements of chronic disease management, while oral delivery platforms aim to expand patient access and market reach. These innovations demand close integration of formulation science, pharmacokinetics, and manufacturing scalability to ensure clinical and commercial success.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.